Pregabalin serum levels in apprehended drivers

Forensic Science International

Volumn 243, Issue , 2014, Pages 112-116

  Kriikku, Pirkko ^a,b   Wilhelm, Lars ^c   Rintatalo, Janne ^d   Hurme, Jukka ^a   Kramer, Jan ^c,e   Ojanperä, Ilkka ^b  

^a Vita Laboratory   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LADR GmbH MVZ Dr Kramer and Colleagues   (Germany)

^d National Bureau of Investigation Finland   (Finland)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Driving; Drugs of abuse; DUID; Pregabalin

Indexed keywords

AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIS; PREGABALIN; PSYCHOTROPIC AGENT; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CAR DRIVER; CAR DRIVING; CONTROLLED STUDY; DRIVING ABILITY; DRIVING UNDER THE INFLUENCE OF DRUG; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RETENTION; FEMALE; FINLAND; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIDDLE AGED; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; AGE; BLOOD SAMPLING; DRIVER; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; RECREATION; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; LEGISLATION AND JURISPRUDENCE; LIMIT OF DETECTION; MASS SPECTROMETRY; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; ANALGESICS; AUTOMOBILE DRIVING; CHROMATOGRAPHY, LIQUID; FEMALE; FINLAND; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MIDDLE AGED; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 84904909294     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.06.030     Document Type: Article

References (37)

1. Lyrica EPAR Product Information by European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf, 2009 (accessed 3 October 2013).
2. FDA Highlights of prescribing information, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022488-s004-0211446s025lbl.pdf, 2011 (accessed 3 October 2013).
3. FDA News release 21 June 2007, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108936.htm., 2007 (accessed 3 October 2013).
4. Taylor C.P., Vartanian M.G., Po-Wai Y., Bigge C., Suman-Chauhan N., Hill D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 1993, 14:11-15.
5. May T.W., Rambeck B., Neb R., Jürgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther. Drug Monit. 2007, 29:789-794.
6. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Gründer G., Haen E., Havemann-Reinecke U., JaquenoudSirot E., Kirchherr H., Laux G., Lutz U.C., Messer T., Müller M.J., Pfuhlmann B., Rambeck B., Riederer P., Schoppek B., Stingl J., Uhr M., Ulrich S., Waschgler R., Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011, 44:195-235.
7. Arroyo S., Anhut H., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004, 45:20-27.
8. Härmark L., Puijenbroek E., Grootheest K. Longitudinal monitoring of the safety of drugs by using a web-based system: the case of pregabalin. Pharmacoepidemiol. Drug Saf. 2011, 20:591-597.
9. Busch J., Strand J., Posvar E., Bockbrader H., Radulovic L. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia 1998, 39:58.
10. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45:13-18.
11. Jeffrey S. First treatment approved for fibromyalgia. Medscape Med. News 2007, http://www.medscape.com/viewarticle/558742 (accessed 3 October 2013).
12. Schwan S., Sundström A., Stjernberg E., Hallberg E., Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur. J. Clin. Pharmacol. 2010, 66:947-953.
13. Skopp G., Zimmer G. Pregabalin-ein Arzneistoff mit Missbrauchspotential?. Archiv für Kriminologie 2012, 229:44-54. (in German).
14. A. Ekbäck, B. Ekstedt, Missbruk av pregabalin förekommer-men osäkert hur vanligt, (Pregabalin is being abused but the extent of abuse is not known) Läkartidningen (108) 2011 1501. (in Swedish).
15. Carrus D., Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J. Clin. Psychopharmacol. 2012, 32:839-840.
16. Grosshans M., Mutschler J., Hermann D., Klein O., Mann K. Pregabalin abuse, dependence, and withdrawal: a case report,. Am. J. Psychiatry 2010, 167:869.
17. Vuori E., Ojaperä I., Launiainen T., Nokua J., Ojansivu R.L. Myrkytyskuolemien määrä on kääntynyt laskuun. Suomen Lääkärilehti 2012, 22:1735-1741. (in Finnish).
18. Nomoto M., Tsujii T., Kyaw W., Nishikawa N., Iwaki H., Nagai M. PP033-effects of pregabalin on driving. Clin. Ther. 2013, 35:e28.
19. DIN 32645, Chemische Analytik - Nachweis-, Erfassungs- und Bestimmungsgrenze, in: Chemical analysis - Decision limit, detection limit and determination limit under repeatability conditions - Terms, methods, evaluation, Beuth Verlag, Berlin, 1994.
20. Huber W. Modifikation von DIN 32645 zur Bestimmung der Nachweis-und Erfassungsgrenze. GIT Labor-Fachzeitschrift 2001, 45:1308-1309.
21. Mandal U., Sarkar A.K., Gowda K.V., Agarwal S., Bose A., Bhaumik U., et al. Determination of pregabalin in human plasmausing LC-MS-MS. Chromatographia 2008, 67:237-243.
22. Kriikku P., Wilhelm L., Rintatalo J., Hurme J., Kramer J., Ojanperä I. Prevalence and blood concentrations of desoxypipradrol (2-DPMP) in drivers suspected of driving under the influence of drugs and in post-mortem cases. Forensic Sci. Int. 2013, 226:146-151.
23. Lottner-Nau S., Övgüer B., Paul L.D., Graw M., Sachs H., Roider G. Abuse of pregabalin-results of the postmortem toxicology from 2010 to 2012. Toxichem. Krimtech. 2013, 80:339-342.
24. Button J., Berry D., Holt D.W. Two fatalities involving pregabalin. Toxichem. Krimtech. 2010, 77:247-248.
25. Schifano F., D'Offizi S., Piccione M., Corazza O., Deluca P., Davey Z., Di Melchiorre G., Di Furia L., Farrs M., Flesland Liv, Mannonen M., Majava A., Pagani S., Peltoniemi T., Siemann H., Skutle A., Torrens M., Pezzolesi C., van der Kreeft P., Scherbaum N. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 2011, 80:118-122.
26. Filipetto F.A., Zipp C.P., Coren J.S. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010, 110:605-607.
27. Launiainen T., Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test. Anal. 2013, 6:308-316.
28. Randinitis E.J., Posvar E.L., Alvey C.W., Sedman A.J., Cook J.A., Bockbrader H.N. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 2003, 43:277-283.
29. Jones A.W., Holmgren A., Holmgren P. High concentrations of diazepam and nordiazepam in blood of impaired drivers: association with age, gender and spectrum of other drugs present. Forensic Sci. Int. 2004, 146:1-7.
30. Hindmarch I., Trick L., Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 2005, 183:133-143.
31. Zacny J.P., Paice J.A., Coalson D.W. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol. Biochem. Behav. 2012, 100:560-565.
32. Highlights of prescribing information (Lyrica), http://labeling.pfizer.com/ShowLabeling.aspx?id=561, 2013 (accessed 24 October 2013).
33. European medicines agency, scientific discussion, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000546/WC500046600.pdf, 2004 (accessed 29 October 2013).
34. Förg A., Hein J., Volkmar K., Winter M., Richter C., Heinz A., Müller C.A. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol. 2012, 47:149-155.
35. Häkkinen M., Vuori E., Kalso E., Gergov M., Ojanperä I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014, 241:1-6.
36. Bobes J., Rubio G., Terán A., Cervera G., López-Gómez V., Vilardaga I., Pérez M. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur. Psychiatry 2012, 27:301-307.
37. Oulis P., Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin. Investig. Drugs 2012, 21:1019-1029.